Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Polysaccharide-Based Magnetic Nanoparticles in Brain Cancer: A Review on the Diagnostic and Therapeutic Potential of Ferumoxytol

Author(s): Christian Chapa Gonzalez* and Pamela Ocampo Valverde

Volume 25, Issue 22, 2025

Published on: 29 October, 2025

Page: [1685 - 1695] Pages: 11

DOI: 10.2174/0113895575400653251008064030

Abstract

Polysaccharide-based iron oxide nanoparticles, particularly PSC-iron oxide nanoparticles, have emerged as promising agents for brain cancer diagnosis and therapy. Originally approved for anemia treatment, PSC-iron oxide nanoparticles leverage extended circulation time, biocompatibility, and MRI contrast capabilities to serve dual diagnostic and therapeutic roles. This review highlights its application in brain tumor management, focusing on enhanced MRI visualization of tumor vascularization and macrophage activity compared to gadolinium-based agents, which improve tumor delineation and treatment monitoring. Additionally, PSC-iron oxide nanoparticles exhibit immune- modulating properties that promote anti-tumor macrophage responses. Preclinical evidence supports the synergistic effects of this approach with existing therapies and its potential in hyperthermia applications. Challenges in clinical translation, including dosage optimization and safety, require further investigation. This review highlights the potential of PSC-iron oxide nanoparticles in current findings to advance precision medicine or nanomedicine approaches for brain tumors.

Keywords: Brain tumor, PSC-iron oxide nanoparticles, magnetic resonance imaging, immunomodulation, nanomedicine, contrast agent.

Next »
Graphical Abstract

[1]
Ilic, I.; Ilic, M. International patterns and trends in the brain cancer incidence and mortality: An observational study based on the global burden of disease. Heliyon, 2023, 9(7), e18222.
[http://dx.doi.org/10.1016/j.heliyon.2023.e18222] [PMID: 37519769]
[2]
Hughes, T.; Harper, A.; Gupta, S.; Frazier, A.L.; van der Graaf, W.T.A.; Moreno, F.; Joseph, A.; Fidler-Benaoudia, M.M. The current and future global burden of cancer among adolescents and young adults: A population-based study. Lancet Oncol., 2024, 25(12), 1614-1624.
[http://dx.doi.org/10.1016/S1470-2045(24)00523-0] [PMID: 39557059]
[3]
Ostrom, Q.T.; Price, M.; Neff, C.; Cioffi, G.; Waite, K.A.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016—2020. Neuro-oncol., 2023, 25(12), iv1-iv99.
[http://dx.doi.org/10.1093/neuonc/noad149] [PMID: 37793125]
[4]
Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2024, 74(3), 229-263.
[http://dx.doi.org/10.3322/caac.21834] [PMID: 38572751]
[5]
Sipos, D.; Raposa, B.L.; Freihat, O.; Simon, M.; Mekis, N.; Cornacchione, P.; Kovács, Á. Glioblastoma: Clinical presentation, multidisciplinary management, and long-term outcomes. Cancers, 2025, 17(1), 146.
[http://dx.doi.org/10.3390/cancers17010146] [PMID: 39796773]
[6]
Angom, R.S.; Nakka, N.M.R.; Bhattacharya, S. Advances in glioblastoma therapy: An update on current approaches. Brain Sci., 2023, 13(11), 1536.
[http://dx.doi.org/10.3390/brainsci13111536] [PMID: 38002496]
[7]
Wermuth, P.J.; Jimenez, S.A. Nephrogenic systemic fibrosis. In: Scleroderma; Varga, J.; Denton, C.; Wigley, F., Eds.; Springer: Boston, MA, 2024; pp. 137-159.
[http://dx.doi.org/10.1007/978-1-4419-5774-0_13]
[8]
Adams, L.C.; Jayapal, P.; Ramasamy, S.K.; Morakote, W.; Yeom, K.; Baratto, L.; Daldrup-Link, H.E. Ferumoxytol-Enhanced MRI in children and young adults: State of the art. AJR Am. J. Roentgenol., 2023, 220(4), 590-603.
[http://dx.doi.org/10.2214/AJR.22.28453] [PMID: 36197052]
[9]
Khan, F.; Pang, L.; Dunterman, M.; Lesniak, M.S.; Heimberger, A.B.; Chen, P. Macrophages and microglia in glioblastoma: Heterogeneity, plasticity, and therapy. J. Clin. Invest., 2023, 133(1), e163446.
[http://dx.doi.org/10.1172/JCI163446] [PMID: 36594466]
[10]
Zhao, W.; Zhang, Z.; Xie, M.; Ding, F.; Zheng, X.; Sun, S.; Du, J. Exploring tumor-associated macrophages in glioblastoma: From diversity to therapy. NPJ Precis. Oncol., 2025, 9(1), 126.
[http://dx.doi.org/10.1038/s41698-025-00920-x]
[11]
Wu, D.; Zhao, J.; Xu, T.; Xiang, H.; Zhao, B.; Gao, L.; Chen, Y. Glioma nanomedicine: Design, fabrication and theranostic application. Coord. Chem. Rev., 2024, 505, 215696.
[http://dx.doi.org/10.1016/j.ccr.2024.215696]
[12]
Van Doren, L.; Steinheiser, M.; Boykin, K.; Taylor, K.J.; Menendez, M.; Auerbach, M. Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions. Am. J. Hematol., 2024, 99(7), 1338-1348.
[http://dx.doi.org/10.1002/ajh.27220] [PMID: 38282557]
[13]
Korangath, P.; Jin, L.; Yang, C.T.; Healy, S.; Guo, X.; Ke, S.; Grüttner, C.; Hu, C.; Gabrielson, K.; Foote, J.; Clarke, R.; Ivkov, R. Iron oxide nanoparticles inhibit tumor progression and suppress lung metastases in mouse models of breast cancer. ACS Nano, 2024, 18(15), 10509-10526.
[http://dx.doi.org/10.1021/acsnano.3c12064] [PMID: 38564478]
[14]
Shan, L. Superparamagnetic iron oxide nanoparticles (SPION) stabilized by alginate. In: Molecular Imaging and Contrast Agent Database (MICAD); National Center for Biotechnology Information (US): Bethesda (MD), 2009.
[15]
Wang, C.Y.; Hong, J.M.; Chen, G.; Zhang, Y.; Gu, N. Facile method to synthesize oleic acid-capped magnetite nanoparticles. Chin. Chem. Lett., 2010, 21(2), 179-182.
[http://dx.doi.org/10.1016/j.cclet.2009.10.024]
[16]
Ibarra, J.; Melendres, J.; Almada, M.; Burboa, M.G.; Taboada, P.; Juárez, J.; Valdez, M.A. Synthesis and characterization of magnetite/PLGA/chitosan nanoparticles. Mater. Res. Express, 2015, 2(9), 095010.
[http://dx.doi.org/10.1088/2053-1591/2/9/095010]
[17]
Roacho-Pérez, J.A.; Rodríguez-Aguillón, K.O.; Gallardo-Blanco, H.L.; Velazco-Campos, M.R.; Sosa-Cruz, K.V.; García-Casillas, P.E.; Rojas-Patlán, L.; Sánchez-Domínguez, M.; Rivas-Estilla, A.M.; Gómez-Flores, V.; Chapa-Gonzalez, C.; Sánchez-Domínguez, C.N. A full set of in vitro assays in chitosan/tween 80 microspheres loaded with magnetite nanoparticles. Polymers, 2021, 13(3), 400.
[http://dx.doi.org/10.3390/polym13030400] [PMID: 33513783]
[18]
Perdani, M.S.; Juliansyah, M.D.; Putri, D.N.; Utami, T.S.; Hudaya, C.; Yohda, M.; Hermansyah, H. Immobilization of cholesterol oxidase in chitosan magnetite material for biosensor application. Int. J. Technol., 2020, 11(4), 754.
[http://dx.doi.org/10.14716/ijtech.v11i4.3484]
[19]
Piosik, E.; Klimczak, P.; Ziegler-Borowska, M.; Chełminiak-Dudkiewicz, D.; Martyński, T. A detailed investigation on interactions between magnetite nanoparticles functionalized with aminated chitosan and a cell model membrane. Mater. Sci. Eng. C, 2020, 109, 110616.
[http://dx.doi.org/10.1016/j.msec.2019.110616] [PMID: 32228924]
[20]
Chapa González, C.; Navarro Arriaga, J.U.; García Casillas, P.E. Physicochemical properties of chitosan–magnetite nanocomposites obtained with different pH. Polym. Polymer Compos., 2021, 29(9_suppl.), S1009-S1016.
[http://dx.doi.org/10.1177/09673911211038461]
[21]
Flores-Urquizo, I.A.; García-Casillas, P.; Chapa-González, C. Desarrollo de nanopartículas magnéticas Fe+32X+21O4(X= Fe, Co y Ni). Recubiertas Con Amino Silano. Rev. Mex. Ing. Biomed., 2017, 38, 402-411.
[http://dx.doi.org/10.17488/RMIB.38.1.36]
[22]
Flores Urquizo, I.A.; Máynez Tozcano, D.I.; Valencia Gómez, L.E.; Roacho Pérez, J.A.; Chapa González, C. Enhancing the cytocompatibility of cobalt‐iron ferrite nanoparticles through chemical substitution and surface modification. Adv. Mater. Interfaces, 2023, 10(18), 2300206.
[http://dx.doi.org/10.1002/admi.202300206]
[23]
Urquizo, I.A.F.; García, T.C.H.; Loredo, S.L.; Galindo, J.T.E.; Casillas, P.E.G.; Barrón, J.C.S.; González, C.C. Effect of aminosilane nanoparticle coating on structural and magnetic properties and cell viability in human cancer cell lines. Part Syst. Charact, 2022, 39(10), 2200106.
[http://dx.doi.org/10.1002/ppsc.202200106]
[24]
Chapa Gonzalez, C.; Martínez Pérez, C.A.; Martínez Martínez, A.; Olivas Armendáriz, I.; Zavala Tapia, O.; Martel-Estrada, A.; García-Casillas, P.E. Development of antibody‐coated magnetite nanoparticles for biomarker immobilization. J. Nanomater., 2014, 2014(1), 978284.
[http://dx.doi.org/10.1155/2014/978284]
[25]
Sodipo, B.K.; Aziz, A.A. Recent advances in synthesis and surface modification of superparamagnetic iron oxide nanoparticles with silica. J. Magn. Mater., 2016, 416, 275-291.
[http://dx.doi.org/10.1016/j.jmmm.2016.05.019]
[26]
Illum, L.; Church, A.E.; Butterworth, M.D.; Arien, A.; Whetstone, J.; Davis, S.S. Development of systems for targeting the regional lymph nodes for diagnostic imaging: In vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm. Res., 2001, 18(5), 640-645.
[http://dx.doi.org/10.1023/A:1011081210142] [PMID: 11465419]
[27]
Roacho-Pérez, J.A.; Ruiz-Hernandez, F.G.; Chapa-Gonzalez, C.; Martínez-Rodríguez, H.G.; Flores-Urquizo, I.A.; Pedroza-Montoya, F.E.; Garza-Treviño, E.N.; Bautista-Villarea, M.; García-Casillas, P.E.; Sánchez-Domínguez, C.N. Magnetite nanoparticles coated with PEG 3350-Tween 80: In vitro characterization using primary cell cultures. Polymers, 2020, 12(2), 300.
[http://dx.doi.org/10.3390/polym12020300]
[28]
Karaagac, O.; Köçkar, H. Improvement of the saturation magnetization of PEG coated superparamagnetic iron oxide nanoparticles. J. Magn. Mater., 2022, 551, 169140.
[http://dx.doi.org/10.1016/j.jmmm.2022.169140]
[29]
McKiernan, E.P.; Moloney, C.; Roy Chaudhuri, T.; Clerkin, S.; Behan, K.; Straubinger, R.M.; Crean, J.; Brougham, D.F. Formation of hydrated PEG layers on magnetic iron oxide nanoflowers shows internal magnetisation dynamics and generates high in-vivo efficacy for MRI and magnetic hyperthermia. Acta Biomater., 2022, 152, 393-405.
[http://dx.doi.org/10.1016/j.actbio.2022.08.033] [PMID: 36007780]
[30]
Chapa, C.; Lara, D.; García, P. Study of the influence of the molecular weight of the polymer used as a coating on magnetite nanoparticles. In: World Congress on Medical Physics and Biomedical Engineering; Lhotska, L.; Sukupova, L.; Lacković, I.; Ibbott, G., Eds.; Springer: Singapore, 2019; pp. 7-11.
[http://dx.doi.org/10.1007/978-981-10-9023-3_2]
[31]
Maurizi, L.; Papa, A.L.; Dumont, L.; Bouyer, F.; Walker, P.; Vandroux, D.; Millot, N. Influence of surface charge and polymer coating on internalization and biodistribution of polyethylene glycol-modified iron oxide nanoparticles. J. Biomed. Nanotechnol., 2015, 11(1), 126-136.
[http://dx.doi.org/10.1166/jbn.2015.1996] [PMID: 26301306]
[32]
Ding, J.; Tao, K.; Li, J.; Song, S.; Sun, K. Cell-specific cytotoxicity of dextran-stabilized magnetite nanoparticles. Colloids Surf. B Biointerfaces, 2010, 79(1), 184-190.
[http://dx.doi.org/10.1016/j.colsurfb.2010.03.053] [PMID: 20427159]
[33]
Villegas-Serralta, E.; Zavala, O.; Flores-Urquizo, I.A.; García-Casillas, P.E.; Chapa González, C. Detection of HER2 through antibody immobilization is influenced by the properties of the magnetite nanoparticle coating. J. Nanomater., 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/7571613]
[34]
Shaterabadi, Z.; Nabiyouni, G.; Soleymani, M. Optimal size for heating efficiency of superparamagnetic dextran-coated magnetite nanoparticles for application in magnetic fluid hyperthermia. Phys. C. Supercond., 2018, 549, 84-87.
[http://dx.doi.org/10.1016/j.physc.2018.02.060]
[35]
Lunov, O.; Syrovets, T.; Büchele, B.; Jiang, X.; Röcker, C.; Tron, K.; Nienhaus, G.U.; Walther, P.; Mailänder, V.; Landfester, K.; Simmet, T. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials, 2010, 31(19), 5063-5071.
[http://dx.doi.org/10.1016/j.biomaterials.2010.03.023] [PMID: 20381862]
[36]
Pedro, L.; Harmer, Q.; Mayes, E.; Shields, J.D. Impact of locally administered carboxydextran‐coated super‐paramagnetic iron nanoparticles on cellular immune function. Small, 2019, 15(20), 1900224.
[http://dx.doi.org/10.1002/smll.201900224] [PMID: 30985079]
[37]
Frtús, A.; Smolková, B.; Uzhytchak, M.; Lunova, M.; Jirsa, M.; Kubinová, Š.; Dejneka, A.; Lunov, O. Analyzing the mechanisms of iron oxide nanoparticles interactions with cells: A road from failure to success in clinical applications. J. Control. Release, 2020, 328, 59-77.
[http://dx.doi.org/10.1016/j.jconrel.2020.08.036] [PMID: 32860925]
[38]
Mehta, K.J. Iron oxide nanoparticles in mesenchymal stem cell detection and therapy. Stem Cell Rev. Rep., 2022, 18, 2234-2261.
[http://dx.doi.org/10.1007/s12015-022-10343-x]
[39]
Hu, S.; Chen, H.; Zhou, F.; Liu, J.; Qian, Y.; Hu, K.; Yan, J.; Gu, Z.; Guo, Z.; Zhang, F.; Gu, N. Superparamagnetic core–shell electrospun scaffolds with sustained release of IONPs facilitating in vitro and in vivo bone regeneration. J. Mater. Chem. B Mater. Biol. Med., 2021, 9(43), 8980-8993.
[http://dx.doi.org/10.1039/D1TB01261D] [PMID: 34494055]
[40]
Gerb, J.; Strauss, W.; Derman, R.; Short, V.; Mendelson, B.; Bahrain, H.; Auerbach, M. Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy. Ther. Adv. Hematol., 2021, 12, 20406207211018042.
[http://dx.doi.org/10.1177/20406207211018042] [PMID: 34104372]
[41]
Deh, K.; Zaman, M.; Vedvyas, Y.; Liu, Z.; Gillen, K.M.C.; O’ Malley, P.; Bedretdinova, D.; Nguyen, T.; Lee, R.; Spincemaille, P.; Jin, M.M.; Kim, J. Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects. Sci. Rep., 2020, 10(1), 1171.
[http://dx.doi.org/10.1038/s41598-020-58219-9]
[42]
Liang, C.; Zhang, X.; Cheng, Z.; Yang, M.; Huang, W.; Dong, X. Magnetic iron oxide nanomaterials: A key player in cancer nanomedicine. VIEW, 2020, 1(3), 20200046.
[http://dx.doi.org/10.1002/VIW.20200046]
[43]
Yu, P.; Zheng, L.; Wang, P.; Chai, S.; Zhang, Y.; Shi, T.; Zhang, L.; Peng, R.; Huang, C.; Guo, B.; Jiang, Q. Development of a novel polysaccharide-based iron oxide nanoparticle to prevent iron accumulation-related osteoporosis by scavenging reactive oxygen species. Int. J. Biol. Macromol., 2020, 165(Pt B), 1634-1645.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.10.016] [PMID: 33049237]
[44]
Elhalawani, H.; Awan, M.J.; Ding, Y.; Mohamed, A.S.R.; Elsayes, A.K.; Abu-Gheida, I.; Wang, J.; Hazle, J.; Gunn, G.B.; Lai, S.Y. Frank, Steven J.; Ginsberg, Lawrence E.; Rosenthal, David I.; Fuller, Clifton D. Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. Sci. Data, 2020, 7(1), 63.
[http://dx.doi.org/10.1038/s41597-020-0392-z]
[45]
Lapusan, R.; Borlan, R.; Focsan, M. Advancing MRI with magnetic nanoparticles: A comprehensive review of translational research and clinical trials. Nanoscale Adv., 2024, 6(9), 2234-2259.
[http://dx.doi.org/10.1039/D3NA01064C] [PMID: 38694462]
[46]
Harvell-Smith, S.; Tung, L.D.; Thanh, N.T.K. Magnetic particle imaging: Tracer development and the biomedical applications of a radiation-free, sensitive, and quantitative imaging modality. Nanoscale, 2022, 14(10), 3658-3697.
[http://dx.doi.org/10.1039/D1NR05670K] [PMID: 35080544]
[47]
Agarwal, R.; Adhikary, S.; Bhattacharya, S.; Goswami, S.; Roy, D.; Dutta, S.; Ganguly, A.; Nanda, S.; Rajak, P. Iron oxide nanoparticles: A narrative review of in-depth analysis from neuroprotection to neurodegeneration. Environmental Science: Advances, 2024, 3(5), 635-660.
[http://dx.doi.org/10.1039/D4VA00062E]
[48]
Zhao, W.; Yu, X.; Peng, S.; Luo, Y.; Li, J.; Lu, L. Construction of nanomaterials as contrast agents or probes for glioma imaging. J. Nanobiotechnol., 2021, 19(1), 125.
[http://dx.doi.org/10.1186/s12951-021-00866-9]
[49]
Nucci, L.P.; Silva, H.R.; Giampaoli, V.; Mamani, J.B.; Nucci, M.P.; Gamarra, L.F. Stem cells labeled with superparamagnetic iron oxide nanoparticles in a preclinical model of cerebral ischemia: A systematic review with meta-analysis. Stem Cell Res. Ther., 2015, 6(1), 27.
[http://dx.doi.org/10.1186/s13287-015-0015-3] [PMID: 25889904]
[50]
Yi, Z.; Liang, W.; Ruan, W.; Hua, W.; Lin, X. A meta-analysis of Au/polypropionic acid nanoparticles loaded with olacetam for the treatment of vascular cognitive impairment. J. Nanosci. Nanotechnol., 2020, 20(12), 7433-7438.
[http://dx.doi.org/10.1166/jnn.2020.18863] [PMID: 32711611]
[51]
Behroozi, Z.; Rahimi, B.; Kookli, K.; Safari, M.S.; Hamblin, M.R.; Razmgir, M.; Janzadeh, A.; Ramezani, F. Distribution of gold nanoparticles into the brain: A systematic review and meta-analysis. Nanotoxicology, 2021, 15(8), 1059-1072.
[http://dx.doi.org/10.1080/17435390.2021.1966116] [PMID: 34591733]
[52]
Janzadeh, A.; Behroozi, Z.; saliminia, F.; Janzadeh, N.; Arzani, H.; Tanha, K.; Hamblin, M.R.; Ramezani, F. Neurotoxicity of silver nanoparticles in the animal brain: A systematic review and meta-analysis. Forensic Toxicol., 2022, 40(1), 49-63.
[http://dx.doi.org/10.1007/s11419-021-00589-4] [PMID: 36454484]
[53]
Guerra Sánchez, K.J.; Gordillo Castillo, N.; Favela Camacho, S.E.; Chapa González, C. Nanoparticles for glioblastoma treatment. IFMBE Proc., 2023, 86, 656-664.
[http://dx.doi.org/10.1007/978-3-031-18256-3_69]
[54]
Wang, Y.; Bastiancich, C.; Newland, B. Injectable local drug delivery systems for glioblastoma: A systematic review and meta -analysis of progress to date. Biomater. Sci., 2023, 11(5), 1553-1566.
[http://dx.doi.org/10.1039/D2BM01534J] [PMID: 36655634]
[55]
Chen, Q.; Yuan, L.; Chou, W.C.; Cheng, Y.H.; He, C.; Monteiro-Riviere, N.A.; Riviere, J.E.; Lin, Z. Meta-analysis of nanoparticle distribution in tumors and major organs in tumor-bearing mice. ACS Nano, 2023, 17(20), 19810-19831.
[http://dx.doi.org/10.1021/acsnano.3c04037] [PMID: 37812732]
[56]
Toth, G.B.; Varallyay, C.G.; Horvath, A.; Bashir, M.R.; Choyke, P.L.; Daldrup-Link, H.E.; Dosa, E.; Finn, J.P.; Gahramanov, S.; Harisinghani, M.; Macdougall, I.; Neuwelt, A.; Vasanawala, S.S.; Ambady, P.; Barajas, R.; Cetas, J.S.; Ciporen, J.; DeLoughery, T.J.; Doolittle, N.D.; Fu, R.; Grinstead, J.; Guimaraes, A.R.; Hamilton, B.E.; Li, X.; McConnell, H.L.; Muldoon, L.L.; Nesbit, G.; Netto, J.P.; Petterson, D.; Rooney, W.D.; Schwartz, D.; Szidonya, L.; Neuwelt, E.A. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int., 2017, 92(1), 47-66.
[http://dx.doi.org/10.1016/j.kint.2016.12.037] [PMID: 28434822]
[57]
Weinstein, J.S.; Varallyay, C.G.; Dosa, E.; Gahramanov, S.; Hamilton, B.; Rooney, W.D.; Muldoon, L.L.; Neuwelt, E.A. Superparamagnetic iron oxide nanoparticles: Diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, A review. J. Cereb. Blood Flow Metab., 2010, 30(1), 15-35.
[http://dx.doi.org/10.1038/jcbfm.2009.192] [PMID: 19756021]
[58]
Muldoon, L.L.; Sàndor, M.; Pinkston, K.E.; Neuwelt, E.A. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery, 2005, 57(4), 785-796.
[http://dx.doi.org/10.1227/01.NEU.0000175731.25414.4c] [PMID: 16239893]
[59]
Dósa, E.; Guillaume, D.J.; Haluska, M.; Lacy, C.A.; Hamilton, B.E.; Njus, J.M.; Rooney, W.D.; Kraemer, D.F.; Muldoon, L.L.; Neuwelt, E.A. Magnetic resonance imaging of intracranial tumors: Intra-patient comparison of gadoteridol and ferumoxytol. Neuro-oncol., 2011, 13(2), 251-260.
[http://dx.doi.org/10.1093/neuonc/noq172] [PMID: 21163809]
[60]
Varallyay, C.G.; Nesbit, E.; Fu, R.; Gahramanov, S.; Moloney, B.; Earl, E.; Muldoon, L.L.; Li, X.; Rooney, W.D.; Neuwelt, E.A. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J. Cereb. Blood Flow Metab., 2013, 33(5), 780-786.
[http://dx.doi.org/10.1038/jcbfm.2013.36] [PMID: 23486297]
[61]
Hamilton, B.E.; Nesbit, G.M.; Dosa, E.; Gahramanov, S.; Rooney, B.; Nesbit, E.G.; Raines, J.; Neuwelt, E.A. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am. J. Roentgenol., 2011, 197(4), 981-988.
[http://dx.doi.org/10.2214/AJR.10.5992] [PMID: 21940589]
[62]
Barajas, R.F.; Hamilton, B.E.; Schwartz, D.; McConnell, H.L.; Pettersson, D.R.; Horvath, A.; Szidonya, L.; Varallyay, C.G.; Firkins, J.; Jaboin, J.J.; Kubicky, C.D.; Raslan, A.M.; Dogan, A.; Cetas, J.S.; Ciporen, J.; Han, S.J.; Ambady, P.; Muldoon, L.L.; Woltjer, R.; Rooney, W.D.; Neuwelt, E.A. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression. Neuro-oncol., 2019, 21(4), 517-526.
[http://dx.doi.org/10.1093/neuonc/noy160] [PMID: 30277536]
[63]
Iv, M.; Samghabadi, P.; Holdsworth, S.; Gentles, A.; Rezaii, P.; Harsh, G.; Li, G.; Thomas, R.; Moseley, M.; Daldrup-Link, H.E.; Vogel, H.; Wintermark, M.; Cheshier, S.; Yeom, K.W. Quantification of macrophages in high-grade gliomas by using ferumoxytol-enhanced MRI: A pilot study. Radiology, 2019, 290(1), 198-206.
[http://dx.doi.org/10.1148/radiol.2018181204] [PMID: 30398435]
[64]
Hamilton, B.E.; Barajas, R.; Nesbit, G.M.; Fu, R.; Ambady, P.; Taylor, M.; Neuwelt, E.A. Ferumoxytol-Enhanced MRI is not inferior to gadolinium-enhanced MRI in detecting intracranial metastatic disease and metastasis size. AJR Am. J. Roentgenol., 2020, 215(6), 1436-1442.
[http://dx.doi.org/10.2214/AJR.19.22187] [PMID: 33052739]
[65]
Qiao, R.; Fu, C.; Forgham, H.; Javed, I.; Huang, X.; Zhu, J.; Whittaker, A.K.; Davis, T.P. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Adv. Drug Deliv. Rev., 2023, 197, 114822.
[http://dx.doi.org/10.1016/j.addr.2023.114822] [PMID: 37086918]
[66]
Dadfar, S.M.; Roemhild, K.; Drude, N.I.; von Stillfried, S.; Knüchel, R.; Kiessling, F.; Lammers, T. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev., 2019, 138, 302-325.
[http://dx.doi.org/10.1016/j.addr.2019.01.005] [PMID: 30639256]
[67]
Zheng, Y.; Jiang, B.; Guo, H.; Zhang, Z.; Chen, B.; Zhang, Z.; Wu, S.; Zhao, J. The combinational nano-immunotherapy of ferumoxytol and poly(I:C) inhibits melanoma via boosting antiangiogenic immunity. Nanomedicine, 2023, 49, 102658.
[http://dx.doi.org/10.1016/j.nano.2023.102658] [PMID: 36708910]
[68]
Zanganeh, S.; Hutter, G.; Spitler, R.; Lenkov, O.; Mahmoudi, M.; Shaw, A.; Pajarinen, J.S.; Nejadnik, H.; Goodman, S.; Moseley, M.; Coussens, L.M.; Daldrup-Link, H.E. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol., 2016, 11(11), 986-994.
[http://dx.doi.org/10.1038/nnano.2016.168]
[69]
Zhang, W.; Cao, S.; Liang, S.; Tan, C.H.; Luo, B.; Xu, X.; Saw, P.E. Differently charged super-paramagnetic iron oxide nanoparticles preferentially induced m1-like phenotype of macrophages. Front. Bioeng. Biotechnol., 2020, 8, 537.
[http://dx.doi.org/10.3389/fbioe.2020.00537] [PMID: 32548111]
[70]
Wang, G.; Serkova, N.J.; Groman, E.V.; Scheinman, R.I.; Simberg, D. Feraheme (Ferumoxytol) is recognized by proinflammatory and anti-inflammatory macrophages via scavenger receptor type AI/II. Mol. Pharm., 2019, 16(10), 4274-4281.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b00632] [PMID: 31556296]
[71]
zhao, J.; Zhang, Z.; Xue, Y.; Wang, G.; Cheng, Y.; Pan, Y.; Zhao, S.; Hou, Y. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I: C) promote melanoma regression. Theranostics, 2018, 8(22), 6307-6321.
[http://dx.doi.org/10.7150/thno.29746] [PMID: 30613299]
[72]
Li, Y.; Thamizhchelvan, A.M.; Ma, H.; Padelford, J.; Zhang, Z.; Wu, T.; Gu, Q.; Wang, Z.; Mao, H. A subtype specific probe for targeted magnetic resonance imaging of M2 tumor-associated macrophages in brain tumors. Acta Biomater., 2025, 194, 336-351.
[http://dx.doi.org/10.1016/j.actbio.2025.01.003] [PMID: 39805525]
[73]
Chen, B.; Xing, J.; Li, M.; Liu, Y.; Ji, M. DOX@Ferumoxytol-Medical Chitosan as magnetic hydrogel therapeutic system for effective magnetic hyperthermia and chemotherapy in vitro. Colloids Surf. B Biointerfaces, 2020, 190, 110896.
[http://dx.doi.org/10.1016/j.colsurfb.2020.110896] [PMID: 32114270]
[74]
Liu, X.; Zhang, Y.; Wang, Y.; Zhu, W.; Li, G.; Ma, X.; Zhang, Y.; Chen, S.; Tiwari, S.; Shi, K.; Zhang, S.; Fan, H.M.; Zhao, Y.X.; Liang, X.J. Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy. Theranostics, 2020, 10(8), 3793-3815.
[http://dx.doi.org/10.7150/thno.40805] [PMID: 32206123]
[75]
Chapa González, C. Magneto hyperthermia. Diagnosis and Treatment of Cancer using Thermal Therapies, 2023, 244-265.
[http://dx.doi.org/10.1201/9781003342663-13]
[76]
Dallet, L.; Stanicki, D.; Voisin, P.; Miraux, S.; Ribot, E.J. Micron-sized iron oxide particles for both MRI cell tracking and magnetic fluid hyperthermia treatment. Sci. Rep., 2021, 11, 3286.
[http://dx.doi.org/10.1038/s41598-021-82095-6]
[77]
Fantechi, E.; Castillo, P.M.; Conca, E.; Cugia, F.; Sangregorio, C.; Casula, M.F. Assessing the hyperthermic properties of magnetic heterostructures: The case of gold–iron oxide composites. Interface Focus, 2016, 6(6), 20160058.
[http://dx.doi.org/10.1098/rsfs.2016.0058] [PMID: 27920896]
[78]
Leonel, A.G.; Mansur, A.A.P.; Carvalho, S.M.; Outon, L.E.F.; Ardisson, J.D.; Krambrock, K.; Mansur, H.S. Tunable magnetothermal properties of cobalt-doped magnetite–carboxymethylcellulose ferrofluids: Smart nanoplatforms for potential magnetic hyperthermia applications in cancer therapy. Nanoscale Adv., 2021, 3(4), 1029-1046.
[http://dx.doi.org/10.1039/D0NA00820F] [PMID: 36133299]
[79]
Manescu Paltanea, V.; Antoniac, I.; Paltanea, G.; Nemoianu, I.V.; Mohan, A.G.; Antoniac, A.; Rau, J.V.; Laptoiu, S.A.; Mihai, P.; Gavrila, H.; Al-Moushaly, A.R.; Bodog, A.D. Magnetic hyperthermia in glioblastoma multiforme treatment. Int. J. Mol. Sci., 2024, 25(18), 10065.
[http://dx.doi.org/10.3390/ijms251810065] [PMID: 39337552]
[80]
Lee, K.C.; Krueger, S.A.; Buelow, K.; Galoforo, S.; Torma, J.; Grills, I.S.; Wilson, G.D.; Marples, B. The use of ferumoxytol and T2*-weighted magnetic resonance imaging for noninvasive assessment of changes in tumor vascularity during radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 2016, 96(2 Supplement), E575-E576.
[http://dx.doi.org/10.1016/j.ijrobp.2016.06.2069]
[81]
Lehrman, E.D.; Plotnik, A.N.; Hope, T.; Saloner, D. Ferumoxytol-enhanced MRI in the peripheral vasculature. Clin. Radiol., 2019, 74(1), 37-50.
[http://dx.doi.org/10.1016/j.crad.2018.02.021] [PMID: 29731126]
[82]
Gahramanov, S.; Raslan, A.M.; Muldoon, L.L.; Hamilton, B.E.; Rooney, W.D.; Varallyay, C.G.; Njus, J.M.; Haluska, M.; Neuwelt, E.A. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: A pilot study. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79(2), 514-523.
[http://dx.doi.org/10.1016/j.ijrobp.2009.10.072] [PMID: 20395065]
[83]
Barajas, R.F.; Schwartz, D.; McConnell, H.L.; Kersch, C.N.; Li, X.; Hamilton, B.E.; Starkey, J.; Pettersson, D.R.; Nickerson, J.P.; Pollock, J.M.; Fu, R.F.; Horvath, A.; Szidonya, L.; Varallyay, C.G.; Jaboin, J.J.; Raslan, A.M.; Dogan, A.; Cetas, J.S.; Ciporen, J.; Han, S.J.; Ambady, P.; Muldoon, L.L.; Woltjer, R.; Rooney, W.D.; Neuwelt, E.A. Distinguishing extravascular from intravascular ferumoxytol pools within the brain: Proof of concept in patients with treated glioblastoma. AJNR Am. J. Neuroradiol., 2020, 41(7), 1193-1200.
[http://dx.doi.org/10.3174/ajnr.A6600] [PMID: 32527840]
[84]
Israel, L.L.; Galstyan, A.; Holler, E.; Ljubimova, J.Y. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J. Control. Release, 2020, 320, 45-62.
[http://dx.doi.org/10.1016/j.jconrel.2020.01.009] [PMID: 31923537]
[85]
Singh, N.; Jenkins, G.J.S.; Asadi, R.; Doak, S.H. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev., 2010, 1(1), 5358.
[http://dx.doi.org/10.3402/nano.v1i0.5358]
[86]
Yarjanli, Z.; Ghaedi, K.; Esmaeili, A.; Rahgozar, S.; Zarrabi, A. Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress, and protein aggregation. BMC Neurosci., 2017, 18(1), 51.
[http://dx.doi.org/10.1186/s12868-017-0369-9] [PMID: 28651647]
[87]
Irrsack, E.; Aydin, S.; Bleckmann, K.; Schuller, J.; Dringen, R.; Koch, M. Local administrations of iron oxide nanoparticles in the prefrontal cortex and caudate putamen of rats do not compromise working memory and motor activity. Neurotox. Res., 2024, 42(1), 6.
[http://dx.doi.org/10.1007/s12640-023-00684-x] [PMID: 38133743]
[88]
Feraheme™ (ferumoxytol) injection. 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf

Rights & Permissions Print Cite
Article Metrics
30
2
Wayfinder Image
© 2026 Bentham Science Publishers | Privacy Policy